4 articles
The US FDA has reportedly shelved its fast-track drug review voucher program initiated during the Trump administration amid concerns over political influence and leadership instability. While some dru
FDA Commissioner Marty Makary resigned after clashing with pharmaceutical executives and lobbyists over drug approvals and regulatory policies. Acting Commissioner Kyle Diamantas is expected to lead t
FDA Commissioner Dr. Marty Makary resigned amid political pressure, triggering an initial biotech rally. Analysts warn the leadership vacuum may delay drug approvals and increase market volatility.
FDA Commissioner Marty Makary resigned after President Trump moved to fire him, leaving the agency at a crossroads. Deputy Commissioner Kyle Diamantas will serve as acting commissioner, having previou
ChemBrief